+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07288177

Phase 2 Open-Label Study of Rina-S Monotherapy in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Led by Genmab · Updated on 2026-11-03

240

Participants Needed

102

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, effectiveness, and how the body processes Rina-S when used alone to treat adults with locally advanced or metastatic non-small cell lung cancer NSCLC, specifically adenocarcinoma type. This Phase 2, open-label study includes participants who have cancer resistant to prior treatments and may or may not have certain genetic changes. The study is conducted worldwide with up to about 240 participants. Participants will receive Rina-S through intravenous infusion as the only treatment. The treatment is given in cycles lasting 3 weeks each, with each participant expected to undergo treatment for about 12 months on average. If the cancer remains stable or improves and there are no serious problems, participants can continue treatment while the study is ongoing. Multiple visits to the study clinic occur in each cycle to receive treatment and monitoring. During the study visits, participants will have tests such as blood draws, heart activity recordings, and imaging like X-rays to monitor safety and how well Rina-S works. Researchers will measure outcomes including tumor response, disease control, progression-free survival, overall survival, drug levels in the blood, immune response to the drug, and side effects. Participation may last several years, with key outcome assessments spanning up to about four years after starting treatment.

CONDITIONS

Brief Title

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Research Team

G

Genmab Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here